ADVA
9.4.2020 09:02:04 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Serverius, one of the Netherlands’ largest data center service suppliers, is leveraging its FSP 3000 TeraFlex™ terminal to massively increase the capacity of its deployed infrastructure. By utilizing the industry’s most comprehensive and scalable solution, Serverius is answering fierce growth in demand for its connectivity, colocation and data security services. With its ultra-flexible bandwidth modulation, TeraFlex™ enables Serverius to harness previously unused spectrum, unlocking new value in its existing fiber network. The highly compact 1RU platform optimizes all optical paths and ensures the lowest cost per bit for all fiber links. By enabling super-channels of up to 1200Gbit/s and a total capacity of 7.2Tbit/s, TeraFlex™ empowers Serverius to provide Dutch and international enterprises with a new level of capacity and throughput.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200409005014/en/
“By harnessing the very latest innovation, we’re bringing a new level of bandwidth capacity and service quality to businesses throughout the Netherlands and beyond. The ADVA FSP 3000 TeraFlex™ is key to our mission of providing world-class data center connectivity. And, with its space- and power-efficiency, it also ensures that our services remain highly affordable today and sustainable for the future,” said Sergey Petukhin, head of connectivity infrastructure, Serverius. “This deployment unlocks the full potential of our network. Now we can meet rapidly rising data demand and be sure that our infrastructure is ready to scale when our clients need even more capacity. What’s more, the openness and programmability of TeraFlex™ mean that we’re free to harness the benefits of tomorrow’s innovation without being tied to any one vendor.”
Serverius’ new solution is built on the ADVA FSP 3000 TeraFlex™, which uses software-defined fractional QAM modulation and adaptive baud rate capabilities to support 1200Gbit/s streams. By retrieving optical channel conditions via network telemetry, the platform determines the best possible capacity and spectral efficiency for each light path. This enables Serverius to exploit untapped capacity in its existing infrastructure without the cost of a complete system upgrade. Each 1RU terminal can also support up to three cards, providing easy access to capacity up to 7.2Tbit/s. What’s more, Serverius is also harnessing ADVA’s MicroMux™QSFP28 plug, which converts 100GbE client ports into ten 10GbE ports, further reducing cost, rack space and operational complexity. Cloud solution specialists Exclusive Networks also played a key role in deploying the technology.
“Serverius has a clear vision of what businesses need and a bold strategy for delivering it. By leveraging our most advanced technologies to massively increase the capacity of its fiber plant, the Netherlands’ fastest-growing cloud connectivity provider is offering its customers a vital competitive edge. With our TeraFlex™, Serverius has the power to flexibly respond to soaring data requirements and help businesses achieve their full potential,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “The strong and long-lasting relationship we have with the Serverius team was also crucial to the success of this project. By working closely with their people, we’ve been able to ensure that the new solution meets all of their particular needs while maximizing the value of their deployed infrastructure.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200409005014/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom